Marc Ferrante News Today

Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn's disease, according to a new study.

Researchers compared the rates of discontinuation after 1 year due to lack of efficacy.

CHICAGO — Biologic-naive patients treated with vedolizumab and ustekinumab for Crohn’s disease had similar rates of clinical response and remission, although mucosal healing and biologic treatment persistence differed at 36 months.“Crohn’s disease is characterized by chronic gastrointestinal inflammation that often requires lifelong treatment,” Marc Ferrante, MD,

- CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2 - Crohns disease is a chronic, systemic...

ABBVie today announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease. 1 In this study, patients who responded to 12 weeks of risankizumab intravenous induction treatment were re-randomized to receive risankizumab 180 ...